Mosaic ImmunoEngineering Inc.
CPMV · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.88 | 0.15 | 0.01 |
| FCF Yield | -2.71% | -1.64% | -2.79% | -2.28% |
| EV / EBITDA | -16.37 | 1,185.92 | -19.02 | -16.42 |
| Quality | ||||
| ROIC | 7.28% | 0.83% | 11.50% | 13.62% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.71 | 1.61 | 0.16 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 7.35% | 30.87% | -5.12% | 0.83% |
| Safety | ||||
| Net Debt / EBITDA | -3.35 | 132.89 | -2.95 | -2.03 |
| Interest Coverage | -14.58 | -16.66 | -17.23 | -13.76 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |